Ottobock SE & Co. KGaA has signed an agreement to sell its Human Mobility business unit to Invacare, now DHCare, marking a significant strategic shift for one of the world’s best-known prosthetics and orthotics companies.
The agreement was signed on 19 June 2026, with the transaction expected to close in the second half of 2026. Ottobock says the sale will allow the company to concentrate more strongly on its core business, especially prosthetics and neuro-orthotics.
The Human Mobility business includes Ottobock’s wheelchair activities. Ottobock’s wheelchair portfolio has included manual and power wheelchairs, children’s wheelchairs, rehab buggies, and seating and positioning solutions.
Strategic Focus on Core Growth Areas
Ottobock CEO Oliver Jakobi said the sale of the wheelchair business is part of a deliberate effort to sharpen the company’s strategic focus.
“By selling our wheelchair business, we are sharpening our strategic focus on our core business,” Jakobi said in the company announcement. “At the same time, with DHCare we have found the right investor for Human Mobility. The team has built a technologically leading business with strong clinical credibility and close customer relationships. We are convinced that Human Mobility has the best opportunities for growth in its new environment.”
The move follows a period in which Ottobock has increasingly emphasised growth in prosthetics, neuro-orthotics, digital care pathways and patient care. At OTWorld 2026, the company highlighted innovation in prosthetics and neuro-orthotics, including digital applications designed to support patient care organisations and improve clinical workflow.
DHCare Expands Its European Mobility Business
For DHCare, the acquisition represents an expansion of its European mobility platform. DHCare is linked to the combination of Direct Healthcare Group and Invacare, and has been positioning itself as a major provider of mobility and care solutions across Europe.
According to DHCare’s own announcement, the transaction is intended to strengthen its mobility portfolio and expand its position in specialist mobility.
German media reports indicate that the transaction includes the German Human Mobility companies and the Dutch children’s wheelchair specialist veldink4Kids, with the aim of supporting continuity for employees, customers and the business.
Why the Sale Matters for O&P and Rehabilitation Markets
For the global O&P and rehabilitation sector, this is more than a corporate divestment. It shows how major medical technology groups are rethinking portfolio focus and capital allocation.
Ottobock has long been associated with both high-end prosthetics and broader mobility solutions. Selling the wheelchair division suggests a clearer strategic separation between:
- Prosthetics and neuro-orthotics as Ottobock’s future growth focus
- Wheelchairs and seating as part of a larger specialist mobility platform under DHCare
This reflects a wider trend in rehabilitation technology: companies are increasingly choosing whether they want to compete as broad mobility groups or as focused technology leaders in specific clinical categories.
Implications for the IMEA Region
For the Middle East, Africa, Central Asia and South Asia, the transaction may have several practical implications.
Ottobock remains a major brand across IMEA prosthetic and orthotic markets, particularly in advanced prosthetic components, microprocessor technologies, orthotic solutions and clinical education. A stronger corporate focus on prosthetics and neuro-orthotics may lead to more attention on these categories across emerging and growth markets.
At the same time, wheelchair users, rehabilitation hospitals and distributors will be watching how the transition affects product continuity, spare parts, service support and regional distribution arrangements for Ottobock Human Mobility products.
In many IMEA countries, wheelchair provision and seating services are already under pressure because of limited reimbursement, uneven service capacity and high demand. Any change in ownership or distribution structure can affect availability, pricing, technical support and long-term service confidence.
Potential Opportunities for Specialist Providers
The sale could create opportunities on both sides of the rehabilitation market.
For Ottobock, a narrower focus may support investment in areas such as:
- Microprocessor prosthetics
- Advanced prosthetic feet and knees
- Neuro-orthotics
- Digital fitting and care pathways
- Patient care networks
- Education and clinical support
For DHCare, the acquisition may strengthen its specialist mobility offering in areas such as:
- Manual wheelchairs
- Power wheelchairs
- Paediatric wheelchairs
- Seating and positioning
- Rehab buggies
- Complex mobility solutions
This type of portfolio alignment could benefit clinicians if it results in clearer product strategies, stronger service networks and more focused innovation.
However, the real impact will depend on execution. Customers in IMEA markets will need reassurance on product availability, warranty arrangements, technical service, clinical training and continuity of local partnerships.
A Reminder That Rehabilitation Technology Is Consolidating
The transaction also highlights continued consolidation and restructuring across the rehabilitation technology sector.
In recent years, O&P and mobility companies have increasingly faced pressure to scale, focus, invest in digital workflows, improve profitability and compete across global markets. As companies become publicly listed or investor-backed, portfolio discipline becomes more important.
Ottobock’s decision to sell Human Mobility fits this pattern. It allows the company to concentrate on higher-priority growth areas while placing the wheelchair business with a buyer more focused on mobility solutions.
For clinicians, distributors and rehabilitation providers, this reinforces the need to track corporate ownership changes. A brand name may remain familiar, but ownership, distribution strategy, product development priorities and support structures can change.
What IMEA Distributors and Clinics Should Watch
Distributors and clinical providers across IMEA markets should monitor several issues as the transaction moves towards completion:
- Will existing Ottobock wheelchair distribution agreements transfer to DHCare?
- Will local product registrations need to be updated?
- Will spare parts and warranty arrangements remain unchanged?
- Will pricing or payment terms change after completion?
- Will paediatric wheelchair products such as veldink4Kids be expanded internationally?
- Will DHCare appoint new distributors in markets where Ottobock previously handled mobility products?
- Will Ottobock increase commercial focus on prosthetics and neuro-orthotics in the region?
These questions will matter especially in markets where tenders, government purchasing and hospital contracts depend on stable supply chains and recognised regulatory responsibility.
Focus Can Be Positive, But Continuity Is Essential
Ottobock’s sale of its Human Mobility business to DHCare is a clear signal that the company wants to sharpen its identity around prosthetics and neuro-orthotics. For an O&P profession that continues to see rapid innovation in powered systems, microprocessor control, digital workflows and neurorehabilitation, this focus may strengthen Ottobock’s role in its most recognised categories.
At the same time, wheelchair and seating users need confidence that the Human Mobility portfolio will continue to receive investment, support and clinical development under DHCare.
For IMEA markets, the transaction should be viewed as both a strategic shift and a practical supply-chain event. The headline is corporate focus. The real test will be continuity for patients, clinicians, distributors and rehabilitation services.
As the transaction moves towards expected completion in the second half of 2026, the region’s O&P and rehabilitation community will be watching closely.
- Ottobock announcement via EQS News
- DHCare announcement
- Ottobock company profile
- Ottobock wheelchairs
- Ottobock at OTWorld 2026
- Direct Healthcare Group
- World Health Organization: Assistive Technology
- World Health Organization: Rehabilitation